SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of randomized trials. Lancet. 2000; 355: 1491-1498.
  • 2
    Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998; 1160: 1220-1229.
  • 3
    Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009; 56: 594-605.
  • 4
    Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005; 23: 8253-8261.
  • 5
    Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008; 8: 440-448.
  • 6
    Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004; 91: 483-490.
  • 7
    Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chicob BN. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol. 2002; 81: 191-201.
  • 8
    Feldman BJ, Feldman D. The development of androgen indpendent prostate cancer. Nat Rev Cancer. 2001; 1: 34-45.
  • 9
    Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001; 93: 1687-1697.
  • 10
    Scher HI, Buchanan G, Gerald W, et al. Targeting the androgen receptor: improving outcomes for castration- resistant prostate cancer. Endocr Relat Cancer. 2004; 11: 459-476.
  • 11
    Kelly WK, Sher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993; 149: 607-609.
  • 12
    Nieh PT. Withdrawal phenomenon with the antiadrogen Casodex. J Urol. 1995; 153: 1070-1073.
  • 13
    Small EJ, Carroll PR. Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994; 43: 408-410.
  • 14
    Gomella LG, Ismail M, Nathan FE. Antiandrogen withdrawal syndrome with nilutamide. J Urol. 1997; 157: 1366.
  • 15
    Huan SD, Gerridzen RG, Yau JC, et al. Antiandrogen withdrawal syndrome with nilutamide. Urology. 1997; 49: 632-634.
  • 16
    Dawson NA, McLeod DG. Dramatic PSA declined in response to discontinuation of megestrol acetate in advance prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol. 1995; 153: 1946-1947.
  • 17
    Bisada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstillbestrol. J Urol. 1995; 153: 1944-1945.
  • 18
    Veldscholte J, Berrevoets CA, Mulder E. Studies on the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol. 1994; 49: 341-346.
  • 19
    Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen-independent prostate cancer: effect of prior hormonal therapy. J Urol. 1997; 159: 149-153.
  • 20
    Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001; 58: 1016-1020.
  • 21
    Davis NB, Ryan CW, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int. 2005; 96: 787-790.
  • 22
    Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med. 2004; 22: 299-309.
  • 23
    Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004; 10: 440-448.
  • 24
    Harper ME, Pike A, Peeling WB, Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol. 1974; 60: 117-125.
  • 25
    Koh E, Kanaya J, Namiki M. Adrenal steroids in human prostatic cancer cell lines. Arch Androl. 2001; 46: 117-125.
  • 26
    Small EJ, Baron A, Bok R. Simultaneous and antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997; 80: 1755-1759.
  • 27
    Small EJBA, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997; 157: 1204-1207.
  • 28
    Harris KWV, Bok RA, Kakefuda M, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002; 168: 542-545.
  • 29
    Figg WD, Liu Y, Arlen P, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol. 2005; 173: 790-796.
  • 30
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004; 22: 1025-1033.
  • 31
    Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose of megestrol acetate for patients with advanced prostate carcinoma: CALGB study 9181. Cancer. 2000; 88: 825-834.
  • 32
    Robertson CN, Roberson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996; 88: 908-917.
  • 33
    Smith DC, Redman BG, Flaherty LE, et al. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advance prostate cancer. Urology. 1998; 52: 257-260.
  • 34
    Rosenbaum E, Wygoda M, Gips M, et al. Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 1372.
  • 35
    Shahidi M, Norman AR, Gadd J, et al. Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 2455.
  • 36
    Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007; 13: 1810-1815.
  • 37
    Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009; 2: 609-615.
  • 38
    Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999; 59: 5160-5168.
  • 39
    Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006; 12: 3394-3401.
  • 40
    Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007; 13: 3883-3891.
  • 41
    Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24: 3089-3094.
  • 42
    Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115: 3670-3679.
  • 43
    Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
  • 44
    Hodge JW, Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer. 1995; 63: 231-237.
  • 45
    DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7–1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006; 4: 1-5.
  • 46
    Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007; 178: 1515-1520.
  • 47
    Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28: 1099-1105.
  • 48
    Tannock I, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistance prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 1756-1764.
  • 49
    Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results from the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17: 2506-2513.
  • 50
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
  • 51
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
  • 52
    Garcia JA, Hutson TE, Shepard D, et al. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial. Cancer. 2011; 117: 752-757.
  • 53
    Kikuno N, Urakami S, Nakamura S, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol. 2007; 51: 1252-1258.
  • 54
    Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003; 98: 2592-2598.
  • 55
    Ferrero JM, Chamorey E, Oudard S, et al. Phase II trial evaluating a docetaxelcapecitabine combination as treatment for hormone-refractory prostate cancer. Cancer. 2006; 107: 738-745.
  • 56
    Tester W, Ackler J, Tijani L, et al. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J. 2006; 12: 299-304.
  • 57
    Gross M, Higano C, Pantuck A, et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007; 7: 142.
  • 58
    Horti J, Widmark A, Stenzl A, et al. A randomized, double-blind, placebo controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm. 2009; 24: 175-180.
  • 59
    Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007; 13: 5816-5824.
  • 60
    Cetnar JP, Rosen MA, Vaughn DJ, et al. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC) [abstract e16055]. J Clin Oncol. 2009; 27( suppl): 15S.
  • 61
    Zurita AJ, Liu G, Hutson T, et al. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC) [abstract 5166]. J Clin Oncol. 2009; 27( suppl): 275S.
  • 62
    Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086) [abstract 5061]. J Clin Oncol. 2009; 27( suppl): 249S.
  • 63
    Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase II study. Eur Urol. 2008; 54: 1089-1094.
  • 64
    Ning YM, Arlen PM, Gulley JL, et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-refractory prostate cancer [abstract 5000]. J Clin Oncol. 2008; 26( suppl): 250S.
  • 65
    Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 2532-2539.
  • 66
    Pili R, Rosenthal M, AS1404–203 study group investigators. Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study [abstract 5007]. J Clin Oncol. 2008;( suppl): 251S.
  • 67
    Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008; 14: 6270-6276.
  • 68
    Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009; 15: 3172-3176.
  • 69
    Petrylak DP, Resto-Garces K, Tibyan M, et al. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer [abstract 5156]. J Clin Oncol. 2009; 27( suppl): 272S.
  • 70
    Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract LBA150]. Proc Am Soc Clin Oncol. Genitourinary Cancers Symposium, 2009.
  • 71
    Beer TM, Javle M, Lam GN, et al. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005; 11: 7794-7799.
  • 72
    Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007; 25: 669-674.
  • 73
    Scher HI, Chi KN, De Wit WR, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from the phase III ASCENT2 trial [abstract 4509]. J Clin Oncol. 2010; 28( suppl): 15S.
  • 74
    Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract LBA4511]. J Clin Oncol. 2010; 28( suppl): 18S.
  • 75
    Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002; 6: 2439-2443.
  • 76
    Harzstark AL, Rosenberg JE, Weinberg VK, et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium [published online ahead of print December 29, 2010]. Cancer. doi: 10.1002/cncr.25810.
  • 77
    Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005; 68: 2-9.
  • 78
    Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009; 27: 5431-5438.
  • 79
    Aller AW, Kraus LA, Bissery M-C. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract 1923]. Proc Am Assoc Cancer Res. 2000; 41: 303.
  • 80
    Attard G, Greystoke A, Kaye S, de Bono J. Update on tubulin binding agents. Pathol Biol (Paris). 2006; 54: 72-84.
  • 81
    Bissery M-C, Bouchard H, Riou JF, et al. Preclinical evaluation of TXD258, a new taxoid [abstract 1364]. Proc Am Assoc Cancer Res. 2000; 41: 214.
  • 82
    Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009; 15: 723-730.
  • 83
    Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008; 19: 1547-1552.
  • 84
    de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-1154.
  • 85
    Cabazitaxel [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S.; 2010.
  • 86
    Attard G, Reid AHM, Olmos D, de Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69; 12: 4937-4940.
  • 87
    Attard G, Reid AHM, Yap TY, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26; 4563-4571.
  • 88
    Attard G, Reid AHM, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009; 27: 3742-3748.
  • 89
    Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010; 28: 1489-1495.
  • 90
    de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
  • 91
    Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study [abstract 3084]. J Clin Oncol. 2010; 28( suppl): 15S.
  • 92
    Scher HI, Beer TM. Higano CS, et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC) [abstract 5011]. J Clin Oncol. 2009; 27( suppl): 15S.
  • 93
    Bruno RD, Vasaitis TS, Gediya LK, et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124–1 (TOK-001) analogs: head to head anti-tumor efficacy evaluation of VN/124–1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 2011; 76: 1268-1279.